Introduction
Sir William Osler once remarked that "the future is today," a statement that continues to be pertinent to the current practice of medicine. 1 During the last few decades, many exciting advances in medical technology have positively impacted patient care, a fact not lost in the management of renal cell carcinoma (RCC).
The incidence of kidney cancer has been rising; approximately 62,000 US patients will be diagnosed with kidney cancer in 2015 and approximately 30,000 partial and radical nephrectomies will be performed. 2, 3 The incidence of RCC has been rising in part due to the incidental finding of small renal masses discovered on cross-sectional imaging for the evaluation of different abdominal pathologies. 4 As a result, most newly diagnosed renal cancers are found when confined to the kidney. 4 The prognosis of these patients primarily depends on the stage of their disease; 5-year survival rates range from 90% to 100% for T1a tumors and 0% to 10% for cases with systemic in-were published, but preference was given to publications from the last 10 years and large series. Full-text articles alone were included. Manuscripts were reviewed for pertinence to the subject matter and included as available.
Radical Nephrectomy
Radical nephrectomy is the traditional benchmark management strategy for RCC to which other treatments have been compared. The laparoscopic technique was introduced in the early 1990s and initial studies defined it as a viable and effective surgical technique. 15 Since then, a natural evolution has taken place over the last several years to incorporating robotic assistance. In 2005, Klingler et al 16 provided the initial report on the viability of robotic-assisted radical nephrectomy (RARN). Although their study cohort was small (5 study patients), they showed that standard perioperative indices were acceptable; 1 study patient alone required conversion to hand-assisted laparoscopy due to bleeding. 16 More robust studies have since been published, confirming successful surgical and oncological outcomes for robotic assistance in study patients undergoing radical nephrectomy (Table 1) . [16] [17] [18] [19] [20] Rogers et al 18 described a series of RARN for benign and malignant renal tumors. In their series, the mean operative time was 158 minutes, the mean rate of estimated blood loss (EBL) was 223 cc, the mean tumor size was 5.1 cm, and the mean length of stay (LOS) at the hospital was 2.4 days, all of which confirmed the assertion that RARN is both safe and effective as an option for extirpative renal surgery. 18 Exclusion criteria for RARN are no different than those for laparoscopy. RARN can be performed by either a transperitoneal or retroperitoneal approach. The initial studies describing RARN focused on the transperitoneal approach, and equivalent outcomes with LRN were demonstrated despite different port placements. 16, 17 Given that earlier reports cited the feasibility of performing LRN via the retroperitoneum, robotic assistance was applied to this approach as well. 21 The largest early series was described by Patel et al, 22 in which 10 study patients underwent retroperitoneal RARN. The results showed that this was a safe and feasible alternative to transperitoneal RARN, with the authors citing direct access to the hilum and minimal bowel manipulation as potential benefits of this approach. 22 Rogers et al 18 described a cohort of 42 study patients subject to RARN, of which 39 used the transperitoneal approach and 3 used the retroperitoneal approach. Although this study was limited by its small cohort of study patients whose disease was managed through a retroperitoneal approach, the authors noted that no significant differences were seen between the outcomes of the 2 groups. 18 Studies show a trend toward improved rates of volvement. 5 These numbers highlight the aggressive nature of RCC; however, when diagnosed while the disease is organ-confined, extirpative surgery (radical or partial nephrectomy) renders a 5-year, disease-specific survival rate higher than 90%. [5] [6] [7] Traditionally, kidney surgery is performed through larger open incisions that can result in poor cosmesis and significant pain, contributing to more prolonged patient convalescence. 8 The adoption of minimally invasive approaches to kidney surgery has been widespread with the introduction of laparoscopy, and the boundaries are continually being pushed with the type and complexity of surgeries that can be performed using robotic assistance. In the late 1980s, laparoscopic technology was routinely applied for cholecystectomies, which further advanced the knowledge base and familiarity with laparoscopic equipment and techniques until laparoscopy was adopted for renal surgery.
9,10 Clayman et al 11 performed the first laparoscopic radical nephrectomy (LRN) in 1991, and subsequent series were published showing the feasibility of laparoscopic renal surgery in larger cohorts of study patients. These studies highlighted smaller incisions, reduced rates of postoperative pain, and improved convalescence as benefits of the minimally invasive approach. Despite the advantages of laparoscopy for the patient, the ability to perform complex kidney surgery is limited to high-volume surgeons who have developed advanced laparoscopic skills. 12 The advent of the da Vinci Surgical System (Intuitive Surgical, Sunnyvale, California) has the same advantages of open surgery without the limitations of pure laparoscopy. Specific advantages of robotic assistance include the 3-dimensional stereoscopic view with 10 times magnification, tremor attenuation, and articulating arms with 7 degrees of freedom. Given the more precise movements and shorter learning curves for surgeons, use of the robotic platform is gaining popularity. Although an open approach is arguably a more appropriate option for larger renal tumors (T2-T3), minimally invasive nephron-sparing surgery (NSS) is often utilized for smaller masses and robotic assistance is the preferred method. 12 Robotic assistance is used for the surgical management of both malignant and benign conditions. Reports continue to be published demonstrating large series of study patients undergoing robotic-assisted surgery with positive long-term results. 13, 14 Given its proven durability, this technique is likely to play a prominent role in the future of surgery.
Methods
A systematic literature search was performed of the medical literature. Original articles, editorials, and reviews were utilized. Abstracts and comments were excluded. We did not limit the date for which the reports EBL, narcotic use, and LOS with minimally invasive extirpative renal surgery when compared with open radical nephrectomy (ORN). 17, 23 Despite this, operative times are shorter with ORN and long-term oncological and functional outcomes are similar between the 2 approaches. 17, 23 As such, both can be used for the management of renal tumors. Regarding minimally invasive renal surgery, the superiority of RARN over LRN or hand-assisted laparoscopic radical nephrectomy (HALRN) has never been demonstrated.
Rogers et al 18 acknowledged the lack of superiority but made note of several important benefits associated with robotic assistance, including a fourth robotic arm that provides renal traction to facilitate hilar dissection, the ability to suture ligate hilar vessels similar to an open approach, and the ability to more precisely place Hem-o-Lok clips (Weck Surgical Instruments, Durham, North Carolina) owing to greater degrees of freedom than pure laparoscopic instruments. 18 Other researchers have noted that case studies can be used as training for more technically challenging robotic-assisted NSS. 15, 18 Despite the noted benefits, many series have compared LRN, HALRN, and RARN and found no significant difference in perioperative characteristics and have seen a trend toward increased operative time with RARN. 17, 19, 20 One study suggested that RARN is not cost effective. Yang et al 24 reported data from more than 24,000 patients from the Nationwide Inpatient Sample database who underwent minimally invasive radical nephrectomy (32% of whom underwent RARN), and they found a total cost increase of nearly $12,000 per case associated with RARN over LRN or HALRN without any difference in patient morbidity. 24 Thus, even though RARN is safe and has similar outcomes to traditional laparoscopic approaches, this added cost of robotic assistance might outweigh any perceived benefit from the approach. As such, when specifically applied to renal surgery, robotic assistance may be most useful in highly complex radical nephrectomy cases and NSS.
Partial Nephrectomy
NSS is the treatment of choice for a small renal mass. 25 Although the evidence is controversial, most researchers believe that, compared with patients undergoing radical nephrectomy, NSS is associated with at least equivalent rates of survival. 26, 27 An intuitive benefit also exists to preserving renal parenchyma and subsequent long-term renal function, and results from retrospective surgical series support maximizing the preservation of functioning nephrons based on lower level evidence for associated cardiovascular and metabolic benefits with NSS compared with radical nephrectomy. 28 Laparoscopic partial nephrectomy (LPN) is a viable surgical approach for the small renal mass deemed appropriate for NSS, and early surgical series from centers of excellence have noted acceptable oncological outcomes and rapid recovery times. 29, 30 However, the technical difficulty of LPN translates into increased perioperative complications compared with those seen in standard open partial nephrectomy (OPN). 25 Gill et al 31 reported outcomes from 1,800 study patients undergoing partial nephrectomy and found that patients assigned to LPN had a 2.14 times higher risk for developing postoperative complications than those assigned to OPN. Increased rates of complications appeared to be related to the limited, 2-dimensional maneuverability of laparoscopic instruments, which resulted in challenging intracorporeal suturing and a subsequent tendency toward prolonged warm ischemia times (WITs) in all but the most experienced laparoscopic surgeons. 31 With robotic technology, improved visual optics 
Retroperitoneal Approach
The anterior transperitoneal approach to RAPN is less than ideal for posteriorly located tumors due to the extensive renal mobilization required for tumor exposure. Following extensive dissection, adequate exposure can still be suboptimal, particularly in patients with more extensive volumes of perinephric fat. In addition, patients with a history of prior abdominal surgeries may have significant adhesions difficult to manage or release with standard laparoscopic techniques, making transperitoneal access and renal exposure challenging. Approaching posterior tumors (particularly posterior-medial) and some posterior-lateral tumors via the retroperitoneum can minimize these issues. Retroperitoneal access for minimally invasive LPN was first described in 1994. 42 Recently, robotic-assisted retroperitoneal partial nephrectomy (RARPN) has been put into use and is a proven, useful technique for appropriately selected patients and tumors. RARPN can facilitate direct access to posteriorly located tumors and early exposure and isolation of the renal vasculature. The lack of entry into the peritoneum minimizes any manipulation required to the bowel and also makes minimally invasive surgery possible in patients previously considered to be poor candidates due to significant scarring from prior abdominal procedures. and articulating arms have mitigated many of the aforementioned concerns. The main advantages of RAPN are the added dexterity, which allows for more precise tumor manipulation, meticulous dissection to ensure complete tumor excision, a greater ability to rapidly control postexcisional bleeding, and more expedient renorrhaphy to maintain low ischemia times. Oncological indications for RAPN are the same as those for OPN, and technical considerations are similar to what were previously described for RARN.
Several surgical series highlight the success of RAPN (Table 2) , and, by contrast to RARN, RAPN has been shown to be superior to LPN. 13, [32] [33] [34] [35] [36] [37] [38] Multiple studies confirm significantly reduced or equivalent operative times, rates of EBL, WITs, and LOS when comparing RAPN with LPN. In addition, greater technical ease and a reduced likelihood of open conversion are both possible with RAPN. 36, 39 The most recent of these studies was performed by Wu et al 40 in which they analyzed 146 and 91 study patients treated with LPN and RAPN, respectively. They demonstrated improved rates of EBL (158 vs 198 cc) and WIT (22.8 vs 31.0 minutes) with equivalent LOS. 40 They also noted a decreased rate of high Clavien-Dindo grade intraoperative complications (1.3% vs 11.7%) when using robotic-assisted technology. 40, 41 RAPN is frequently performed through a transperitoneal approach, which is likely secondary to surgeon preference; however, advocates for transperitoneal surgery highlight the ease of access, the large available working space resulting from the pneumoperitoneum, and more easily recognizable or established anatomical landmarks as specific benefits to their approach not readily appreciated or developed using a retroperitoneal technique. 21 High-volume robotic-assisted surgical centers commonly employ a Weizer et al 43 published the first series describing the retroperitoneal approach, analyzing data from 11 study patients undergoing RARPN. Their results were promising and highlighted the low rate of perioperative morbidity and the ability of the surgeon to address complex posterior tumors. 43 In a large, multiinstitutional cohort involving 227 RARPN cases, researchers compared their results with large, previously published cohorts of OPN and found a decrease in mean rate of EBL (approximately 300 mL) and shortened LOS of at least 4 days in patients undergoing RARPN when compared with OPN; significant differences in WIT were not seen. 44 In addition to these reports, other studies have assessed study patients undergoing RARPN, all of which have highlighted the feasibility of this surgical approach (Table 3) . [43] [44] [45] [46] [47] [48] [49] [50] Access to upper-pole posterior tumors may be difficult due to interference from the eleventh and twelfth ribs. However, select upper-pole tumors can be accessed using this technique, and tumors with a high nephrometry score (greater complexity) can also be successfully treated using the retroperitoneal approach (see Table 3 ). [43] [44] [45] [46] [47] [48] [49] [50] [51] Although obesity adds to the complexity of RAPN, an elevated body mass index does not preclude acceptable patients from undergoing RARPN. In fact, data have shown the feasibility for RARN in patients who are obese. 52 Recognizing selection bias for any technique outside of a randomized clinical trial, 1 published series of RARPN included patients with a mean body mass index of 31 kg/m 2 and noted the feasibility of RARPN in select patients. 48 
Limitations
The main disadvantage associated with robotic-assisted renal surgery is centered on the cost of the technology. At the time of publication, a robotic system costs between $1.0 million and $2.5 million with an annual service agreement of about $100,000. 53 Many centers cannot afford this, a fact that has precluded the widespread, if not universal, adoption of this platform. Despite this, investigators have attempted to address whether or not increased expenditures were offset by decreased perioperative morbidities following procedures performed with robotic assistance. 54, 55 Laydner et al 56 reported a cost analysis of all partial nephrectomies performed at their institution, whether they be robotic-assisted, laparoscopic, or open procedures. They found that increased operating room costs were associated with RAPN when compared with LPN and OPN, but they noted that the total health care expenditure was less when compared with OPN, given the higher costs associated with perioperative morbidity in the OPN cohort. 56 The total cost of LPN was less than RAPN, but LPN is still arguably inferior because of the increased difficulty associated with the laparoscopic technique. 56 Although cost analyses support robotic assistance for nephron-preservation procedures, in the case of radical nephrectomy, in which LRN is rel- tional 5-mm trocar for liver retraction with right-sided renal tumors. 60 The results showed significantly increased mean operative time, mean WIT, and a postoperative decline in renal function when using the LESS-RAPN technique compared with standard RAPN. 60 According to the authors, issues related to working space and collisions were significant, with the robotic arms occupying working space normally required for precise movements. 60 Such technical limitations and concerns regarding perioperative outcomes have been confirmed by other investigators. 61 Improvements have been made to the da Vinci Xi Surgical System (Intuitive Surgical), and its robotic arms are streamlined to allow for more intimate trocar placement and reduced risk for robotic arm collision. However, whether the introduction of this system will allow for greater surgical dexterity in the context of LESS surgery remains to be seen. Regardless, LESS-RAPN may have some role in the future of minimally invasive renal surgery, but significant refinements and greater experience is required before it can be widely adopted.
In addition to the modification of surgical approaches, there has been a push toward innovative intraoperative maneuvers to improve functional outcomes associated with RAPN -in particular, the loss in renal function associated with hilar clamping and atively easy to perform and costs substantially less than RARN, robotic technology affords neither the patient nor the surgeon any clinical or financial benefit.
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Future Directions
Standard multiport laparoscopy is safe and effective in renal surgery, and laparoendoscopic single-site (LESS) surgery has been investigated in the minimally invasive management of renal masses. Theoretical advantages over standard multiport robotics include better cosmetic results and a faster return to daily activities. 57 The LESS surgical platform has been extended to NSS, but it has not been widely adopted owing to the difficulty associated with LESS-LPN. 57 To address this, reports have emerged describing the use of robotic assistance for LESS-partial nephrectomy. 58 Tiu et al 59 reported on a series of 67 LESS-RAPN cases with good results. Their cohort included 20 study patients with tumors larger than 4 cm in diameter (mean, 5.2 cm) and a mean nephrometry score of 8.5; they highlighted the feasibility of this approach even in complex cases.
59
A retrospective, single-center, single-surgeon comparison directly looked at RAPN and LESS-RAPN. 60 Study patients in each cohort were standardized with respect to nephrometry score, tumor size, and other characteristics. Four arms were used for LESS-RAPN, along with an optional addi- warm ischemia for tumor removal. Berg et al 62 proposed the first-assistant sparing technique, which is a method that uses intracorporeal preparation (ICP) for tumor excision and renorrhaphy. Many surgeons use this method, and it involves the pre-placement of all necessary sutures and bulldog clamps as well as a "sliding clip" method for repair of the renal defect. 62 Specifically, sutures are secured to the abdominal wall for easy access following tumor extirpation and bulldog clamps are pre-placed near the hilum. In their study, a cohort of study patients undergoing ICP-RAPN was compared with study patients assigned to consecutive standard RAPN. 62 Their results revealed reduced WITs and operative times for those undergoing ICP-RAPN. 62 Although minimizing WIT is a desired goal, achieving cold ischemia similar to an open approach to partial nephrectomy has also been described. Rogers et al 63 reported their early experience with intracorporeal renal parenchymal cooling and the tumor extraction technique for RAPN in 7 cases. Both transperitoneal and retroperitoneal approaches for RAPN were utilized, and the researchers showed that the intracorporeal perinephric instillation of iced saline flushes resulted in significant renal cooling without lowering core body temperature above 0.5 °C. 63 Mean cold ischemia time was acceptable at 19.6 minutes and, despite no comparison of preoperative and postoperative glomerular filtration rate, this technique could hypothetically facilitate the preservation of renal function. 63 Additional prospective data with this technique are desired, but it is a reasonable option in complex cases in which more delicate work or longer clamp time is anticipated for tumor excision.
The safe duration of renal ischemia is debatable, but any reduction in ischemia is likely to yield positive results. Thus, efforts have been made to completely avoid renal ischemia for select RAPN cases. White et al 64 published one of the first series of RAPN performed without hilar clamping. The results were promising among the 8 participants studied, so the authors concluded that off-clamp partial nephrectomy was a feasible option for the management of small superficial tumors. Since then, several larger series have been published describing the successes of off-clamp partial nephrectomies with tumors of increasing complexity. [65] [66] [67] One multi-institutional study evaluated the outcomes of off-clamp RAPN performed at 5 high-volume centers. 68 When the off-clamp RAPN cases were matched and compared with RAPN cases with standard hilar clamping, decreased operative time (156 vs 185 minutes), decreased decline in renal function (2% vs -6%), and increased rate of EBL (228 vs 158 cc) were seen with off-clamp RAPN. 68 However, some theoretical concerns are associated with this technique. The rate of EBL is significantly higher than what would be expected for similar tumors managed with hilar clamping. In addition, increased bleeding in the renal parenchymal bed could lead to imprecise tumor excision, thus resulting in incomplete tumor resection or inappropriate removal or compromised perfusion of normal parenchyma. Although these concerns have not materialized in recent studies, they must be addressed through the further evaluation of larger study patient cohorts. 68 Currently, off-clamp RAPN is an evolving technique and, given more time, it may be an option that might be safely applied to properly selected patients with renal tumors.
Despite its increasing acceptance in urology, the robotic platform lacks haptic feedback.
69 Tactile sensation as provided by standard open -and even laparoscopic -surgery allows for more precise and delicate dissection. Furthermore, the lack of force recognition can negatively impact patient safety, and this is particularly true during dissection or the manipulation of tenuous anatomical structures. 69 Although haptic feedback has not yet been developed, augmented reality is a technological advance being used to assist with making robotic-assisted renal surgery more user friendly. 70 One systematic literature review examined the utility of augmented-reality techniques in partial nephrectomy. Augmented reality involves the real-time superimposition of preoperative, cross-sectional images on 3-dimensional stereoscopic views of an organ during surgery. The goal is to allow for the early identification of important anatomical landmarks, thus aiding in complete tumor excision with negative margins while also minimizing loss of normal renal parenchyma. 70 Early studies using a variety of in vivo and ex vivo augmented-reality techniques are promising, but none has adequately superimposed preoperative images on tissue with positional changes during surgical dissection. 71, 72 This is a significant factor that limits the applicability of the augmented-reality techniques, but intraoperative image guidance could address this issue in the future. Thus, augmented reality could be a promising adjunct to robotic assistance during renal surgery, but further refinement and clinical research are needed to assess its true applicability.
In addition to technical innovations, the field of robotic-assisted renal surgery has seen advancements in terms of its application to highly complex cases, including the management of RCC and associated inferior vena cava tumor thrombus. However, such patients must be highly selected due to tumor biology and the nature of the tumor thrombi. Nevertheless, small surgical series of study patients with low level 1 and 2 tumor thrombi have been described with acceptable perioperative and oncological outcomes. 73 
Conclusions
Robotic assistance has transformed surgical care for many different patients with various disease states.
Compared with the open approach, robotic-assisted surgery has been shown to improve rates of morbidity and patient satisfaction in patients with renal cell carcinoma and does so without compromising oncological control -this is particularly true for nephron-sparing surgery.
The advantages of robotic-assisted partial nephrectomy compared with laparoscopic partial nephrectomy are well documented, and robotic technology allows for the more widespread adoption of minimally invasive techniques for many patients. Today, robotic-assisted partial nephrectomy is the method of choice for nephron-sparing surgery, when applicable, using either the transperitoneal or retroperitoneal approach. Although robotic-assisted radical nephrectomy is feasible, few real benefits exist to using robotic assistance in this setting, partly because of the ease and decreased cost associated with laparoscopic radical nephrectomy.
Many technical and technological advances to make robotic-assisted partial nephrectomy safer and more effective are on the horizon, but additional experience and scrutiny are necessary to gain widespread adoption. Although selected patients with locally advanced renal cell carcinoma, including inferior vena cava thrombectomy, have undergone robotic-assisted surgery, caution must still be exercised in these more complex clinical scenarios.
Despite the financial concerns associated with the robotic-assisted platform, when compared with open surgery, increased up-front medical costs might be mitigated through reduced rates of perioperative morbidity as well as the subsequent positive impact on societal costs and other factors. Such an area of focus requires added attention in the current era of value-based care.
